Ryan B. Corcoran

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• A single-arm, phase II study of ivonescimab in combination with FOLFOX in advanced HER2-negative gastroesophageal adenocarcinomas.

  Journal of Clinical Oncology · 2026-05-28

• Abstract 5696: RAS(ON) multi-selective inhibitors stimulate the hydrolysis of RAS-GTP to RAS-GDP and drive synergistic combination benefit with KRAS(OFF) inhibitors in G12 mutant tumors

  Cancer Research · 2026-04-03

• Data from Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators

  2026-04-01

• Supplementary Figures S1-S6 from Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators

  2026-04-01

• Quantitative imaging of schwannoma captures heterogeneity and accelerates preclinical testing, revealing distinct impacts of targeted therapies

  bioRxiv (Cold Spring Harbor Laboratory) · 2026-03-26

• Overcoming Adaptive Resistance to KRASG12D Blockade in Pancreatic Cancer through Vertical Pathway Inhibition

  Clinical Cancer Research · 2026-03-09 · 1 citations

• Emerging landscape of KRAS inhibitors in cancer treatment

  Cancer Cell · 2026-01-29 · 10 citations

• ATR Safeguards Epithelial-to-Mesenchymal Transition by Countering R-loops and Enabling Transcription Reprogramming

  Journal of Clinical Investigation · 2026-01-22

• The ADAPT learning cancer treatment system: ARPA-H’s initiative to revolutionize cancer therapy

  Cancer Cell · 2026-01-08 · 1 citations

• Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators

  Cancer Discovery · 2026-01-08 · 3 citations

• MAPK Pathway Mutations Emerge in Mutant IDH1 Inhibitor–Resistant Cholangiocarcinoma and Attenuate the IFN Response

  Clinical Cancer Research · 2025-12-29 · 3 citations

• 498 Integrated scRNAseq, TCR repertoire and spatial transcriptomic analysis reveals immune remodeling induced by combined BRAF/MEK/PD-1 inhibition in metastatic BRAFV600E colorectal cancer

  Regular and Young Investigator Award Abstracts · 2025-11-01

• Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFV600E metastatic colorectal cancer

  Cancer Cell · 2025-08-28 · 22 citations

• Mechanisms of genomic resistance across emerging classes of KRAS inhibitors

  Annals of Oncology · 2025-07-30

• Supplemental Table S1 from TOP1 Mutations and Cross-Resistance to Antibody–Drug Conjugates in Patients with Metastatic Breast CancerPreprint

  2025-05-15

• Data from TOP1 Mutations and Cross-Resistance to Antibody–Drug Conjugates in Patients with Metastatic Breast CancerPreprint

  2025-05-15

• Supplementary Figure S1 from TOP1 Mutations and Cross-Resistance to Antibody–Drug Conjugates in Patients with Metastatic Breast CancerPreprint

  2025-05-15

• Abstract LB289: Clinical resistance to Y220C-mutant p53 reactivators

  Cancer Research · 2025-04-25

• Abstract LB371: Enhancing anti-tumor immunity with dual inhibition of KRASG12Cand PD-1 in colorectal cancer

  Cancer Research · 2025-04-25

• Abstract 664: Integrated scRNAseq and spatial transcriptomic analyses identify immune correlates of response to combined BRAF/MEK/PD-1 inhibition in metastatic colorectal cancer

  Cancer Research · 2025-04-21